Here's Why I Still Wouldn't Touch Teladoc With a 10‑Foot Pole

Core Viewpoint - Teladoc Health, once thriving during the COVID-19 pandemic, is now facing stagnant and declining revenue, leading to concerns about its long-term viability as a company [1][12]. Company Overview - Founded in 2002, Teladoc Health specializes in remote medical appointments and had a successful IPO in 2015, experiencing steady share price growth until the pandemic [2]. - The company's stock price surged 224% from approximately $81 per share in late 2019 to a peak of $263 per share in January 2021 [4]. Current Financial Performance - By the end of 2023, Teladoc's share price had plummeted to $21, representing a 92% decrease from its peak [5]. - As of the latest data, the stock trades around $5, with a market capitalization of $861 million [6][7]. - Revenue for 2023 was reported at $2.6 billion, which is projected to decline by 1% to $2.5 billion in 2024, with further decreases anticipated in subsequent quarters [10]. Competitive Landscape - Teladoc faces significant competition from other telemedicine providers and traditional in-person medical services, with 71% of patients preferring in-person visits according to the National Institutes of Health [8][9]. - The company has struggled to maintain its market position as telemedicine becomes less dominant post-pandemic [9]. Profitability Challenges - Teladoc has never achieved profitability, with a net profit margin of negative 21% during its peak in 2021, improving slightly to negative 8.8% but still indicating ongoing financial struggles [11]. - The company is characterized by a lack of growth and profitability, raising concerns about its future sustainability [12].